Macrogenics Stock Performance
| MGNX Stock | USD 1.44 0.01 0.69% |
The company secures a Beta (Market Risk) of 3.49, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MacroGenics will likely underperform. MacroGenics right now secures a risk of 5.81%. Please verify MacroGenics maximum drawdown, as well as the relationship between the daily balance of power and relative strength index , to decide if MacroGenics will be following its current price movements.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days MacroGenics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, MacroGenics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | MacroGenics Appoints Eric Risser as President and Chief Executive Officer | 08/13/2025 |
2 | Acquisition by Heiden William K of 50500 shares of MacroGenics at 1.52 subject to Rule 16b-3 | 08/19/2025 |
3 | Acquisition by Heiden William K of 49500 shares of MacroGenics at 1.49 subject to Rule 16b-3 | 08/20/2025 |
4 | Tools to monitor MacroGenics Inc. recovery probability - Market Growth Report Safe Capital Growth Trade Ideas - Newser | 08/27/2025 |
5 | Acquisition by Thomas Spitznagel of 30000 shares of MacroGenics at 1.58 subject to Rule 16b-3 | 09/05/2025 |
6 | Sentiment Review What makes MacroGenics Inc stock attractive today - Trade Entry Report Long-Term Safe Investment Ideas - | 09/15/2025 |
7 | Acadian Asset Management LLC Has 2.92 Million Stock Position in MacroGenics, Inc. MGNX - MarketBeat | 09/17/2025 |
8 | Strs Ohio Invests 263,000 in MacroGenics, Inc. MGNX - MarketBeat | 09/25/2025 |
9 | Disposition of 6433 shares by Eric Risser of MacroGenics at 2.56 subject to Rule 16b-3 | 09/29/2025 |
10 | Acquisition by Ezio Bonvini of 16665 shares of MacroGenics subject to Rule 16b-3 | 10/02/2025 |
11 | Weiss Ratings Reaffirms Sell Rating for MacroGenics - MarketBeat | 10/10/2025 |
12 | 3 Promising Penny Stocks With Market Caps Over 100M | 10/22/2025 |
13 | MacroGenics Expected to Announce Earnings on Tuesday - MarketBeat | 10/29/2025 |
14 | Why MacroGenics Inc. stock could rally in 2025 - MA Rumor Smart Allocation Stock Reports - fcp.pa.gov.br | 11/05/2025 |
| Begin Period Cash Flow | 101 M | |
| Total Cashflows From Investing Activities | 149.3 M |
MacroGenics | Build AI portfolio with MacroGenics Stock |
MacroGenics Relative Risk vs. Return Landscape
If you would invest 154.00 in MacroGenics on August 8, 2025 and sell it today you would lose (10.00) from holding MacroGenics or give up 6.49% of portfolio value over 90 days. MacroGenics is currently generating 0.0534% in daily expected returns and assumes 5.8115% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than MacroGenics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MacroGenics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MacroGenics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MacroGenics, and traders can use it to determine the average amount a MacroGenics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0092
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | MGNX | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.81 actual daily | 52 52% of assets are less volatile |
Expected Return
| 0.05 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average MacroGenics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MacroGenics by adding MacroGenics to a well-diversified portfolio.
MacroGenics Fundamentals Growth
MacroGenics Stock prices reflect investors' perceptions of the future prospects and financial health of MacroGenics, and MacroGenics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MacroGenics Stock performance.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (1.65) % | ||||
| Current Valuation | (31.16 M) | ||||
| Shares Outstanding | 63.21 M | ||||
| Price To Earning | (4.54) X | ||||
| Price To Book | 2.32 X | ||||
| Price To Sales | 0.55 X | ||||
| Revenue | 148.34 M | ||||
| Gross Profit | (16.09 M) | ||||
| EBITDA | (57.37 M) | ||||
| Net Income | (66.97 M) | ||||
| Cash And Equivalents | 133.74 M | ||||
| Cash Per Share | 2.18 X | ||||
| Total Debt | 37.46 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 3.30 X | ||||
| Book Value Per Share | 0.74 X | ||||
| Cash Flow From Operations | (68.37 M) | ||||
| Earnings Per Share | (0.57) X | ||||
| Market Capitalization | 91.02 M | ||||
| Total Asset | 261.65 M | ||||
| Retained Earnings | (1.17 B) | ||||
| Working Capital | 161.96 M | ||||
| Current Asset | 342.38 M | ||||
| Current Liabilities | 23.29 M | ||||
About MacroGenics Performance
Evaluating MacroGenics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if MacroGenics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MacroGenics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 62.33 | 59.22 | |
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.54) | (0.56) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.58) | (0.61) |
Things to note about MacroGenics performance evaluation
Checking the ongoing alerts about MacroGenics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MacroGenics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MacroGenics had very high historical volatility over the last 90 days | |
| MacroGenics may become a speculative penny stock | |
| MacroGenics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 148.34 M. Net Loss for the year was (66.97 M) with loss before overhead, payroll, taxes, and interest of (16.09 M). | |
| MacroGenics currently holds about 133.74 M in cash with (68.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| MacroGenics has a poor financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Why MacroGenics Inc. stock could rally in 2025 - MA Rumor Smart Allocation Stock Reports - fcp.pa.gov.br |
- Analyzing MacroGenics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MacroGenics' stock is overvalued or undervalued compared to its peers.
- Examining MacroGenics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MacroGenics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MacroGenics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MacroGenics' stock. These opinions can provide insight into MacroGenics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.